pro-140 monoclonal antibody
mAbexperimental
Clinical trial activity
15 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00110591)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
Viral-entry inhibitor.
- C-C chemokine receptor type 5INHIBITOR
CCR5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109343 ↗
Also known as
- pro 140
- pro 140
- pro-140
- pro-140 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03902522 | Phase 2/Phase 3 (Phase 3) | Jun 25, 2018 | CytoDyn, Inc. |
| NCT05271370 | Phase 2/Phase 3 (Phase 3) | Aug 29, 2017 | CytoDyn, Inc. |
| NCT02737306 | Phase 2 | Nov 1, 2016 | Amarex Clinical Research, CytoDyn, Inc. |
| NCT02990858 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2016 | CytoDyn, Inc. |
| NCT02859961 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2016 | CytoDyn, Inc. |
| NCT02759042 | N/A | Apr 19, 2016 | Amarex Clinical Research, CytoDyn, Inc., Orlando Immunology Center |
| NCT02483078 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2015 | Amarex Clinical Research, CytoDyn, Inc. |
| NCT02355184 | Phase 2 | Nov 1, 2014 | CytoDyn, Inc. |
| NCT02257788 | Phase 2 | Sep 1, 2014 | Drexel University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02175680 | Phase 2 | May 1, 2014 | CytoDyn, Inc. |
| NCT01272258 | Phase 2 | Dec 1, 2013 | CytoDyn, Inc. |
| NCT02438345 | Phase 2 | Nov 1, 2012 | Drexel University, National Institute on Drug Abuse (NIDA) |
| NCT00642707 | Phase 2 | Mar 1, 2008 | CytoDyn, Inc., Progenics |
| NCT00613379 | Phase 2 | Dec 1, 2007 | CytoDyn, Inc., National Institute of Allergy and Infectious Diseases (NIAID), Progenics |
| NCT00110591 | Phase 1 | Apr 1, 2004 | CytoDyn, Inc., Progenics |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytoDyn, Inc. | For profit | 13 | 13 | 4 | 2004 |
| Amarex Clinical Research | For profit | 3 | 0 | 3 | 2015 |
| Progenics | For profit | 3 | 0 | 2 | 2004 |
| Drexel University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 0 | 1 | 2007 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2012 |
| Orlando Immunology Center | Academic/Hospital | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1